Registration
 
All news
Top Stories
Editors' Picks
Crypto
Financial News
Currencies
Market Voices
Companies
Regulators News
Central Banks News
Elena Nikulina
Elena Nikulina

Editas Medicine posts fourth quarter and full year 2025 financial results

Editas Medicine posts fourth quarter and full year 2025 financial results
Editas Medicine earnings and updates

Editas Medicine announced its financial results for the fourth quarter and full year 2025.

The company also shared updates on its business operations and strategic plans. Full details are available in the official press release. Investors and analysts will be watching the biotech firm's performance closely as it continues to advance its gene editing programs.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Bitcoin price prediction based on RSI: Is BTC poised for a new rally?
  • By Oleg Tkachenko
  • 3 hours ago
Bitcoin price prediction based on RSI: Is BTC poised for a new rally?
Editors' Picks
Toncoin becomes Gram: Why Durov restored token's original name
  • By Anastasiia Chabaniuk
  • Yesterday
Toncoin becomes Gram: Why Durov restored token's original name
Editors' Picks
Why Tether flipping Ethereum is a pivotal moment for crypto
  • By Kyle Torpey
  • 15.06.2026
Why Tether flipping Ethereum is a pivotal moment for crypto
Editors' Picks
All Editors' Top Picks

Latest Editas Medicine News

Editas Medicine CEO to join MIT panel on pipeline prioritization at Longwood Healthcare Leaders event
  • By Anastasiia Chabaniuk
  • 12.06.2026
Editas Medicine CEO to join MIT panel on pipeline prioritization at Longwood Healthcare Leaders event
Companies
#Editas Medicine
Editas Medicine adjusts agenda at key investor event
  • By Mikhail Vnuchkov
  • 28.05.2026
Editas Medicine adjusts agenda at key investor event
Companies
#Editas Medicine
Editas Medicine presents new preclinical data on EDIT-401 at EASCongress2026
  • By Anastasiia Chabaniuk
  • 27.05.2026
Editas Medicine presents new preclinical data on EDIT-401 at EASCongress2026
Companies
#Editas Medicine
All Editas Medicine News
  • Oleg Tkachenko
  • 3 hours ago
Bitcoin price prediction based on RSI: Is BTC poised for a new rally?
  • Anastasiia Chabaniuk
  • Yesterday
Toncoin becomes Gram: Why Durov restored token's original name
  • Kyle Torpey
  • 15.06.2026
Why Tether flipping Ethereum is a pivotal moment for crypto
  • Eugene Komchuk
  • 15.06.2026
MiCA deadline: Why crypto companies are leaving Europe
  • Mikhail Vnuchkov
  • 13.06.2026
From “Holy Trinity” to WLD crash: How Arthur Hayes became a market-moving seller
  • Elena Nikulina
  • 3 min ago
Andy Constan: Market for 6-12 month variance swaps on mega caps remains illiquid
  • Oleg Tkachenko
  • 18 min ago
Eric Balchunas: Buffer ETFs expand globally as Europe gains traction
  • Daria Chernytska
  • 27 min ago
Prediction markets become accessible to all on Sui Network, Adeniyi Abiodun notes
  • Ivan Andriyenko
  • 42 min ago
Meb Faber: Compounding should not be interrupted unnecessarily
  • Mikhail Vnuchkov
  • 53 min ago
Michael Pettis: USSR maximized output under soft budget constraints at expense of value
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.
Top News
  • Eugene Komchuk
  • 1 hour ago
Traders Union research: 58% of crypto investors have encountered scams
Traders Union research: 58% of crypto investors have encountered scams
  • Parshwa Turakhiya
  • 3 hours ago
Sam Bankman-Fried weighs token launch after prison sentence
Sam Bankman-Fried weighs token launch after prison sentence
  • Ivan Andriyenko
  • 4 hours ago
U.S. futures rise before Fed rate decision
U.S. futures rise before Fed rate decision
  • Olga Shendetskaya
  • 5 hours ago
Oil falls as Hormuz uncertainty keeps traders cautious
Oil falls as Hormuz uncertainty keeps traders cautious
  • Eugene Komchuk
  • 5 hours ago
Binance risks losing access to EU market over MiCA license issues
Binance risks losing access to EU market over MiCA license issues
Live News
  • Mykhailo Ihnatenko
  • Now
AMD rallies on AI growth as insider selling raises concerns
  • Anton Kharitonov
  • Now
Apple rebounds after selloff as AI strategy supports shares
  • Anton Kharitonov
  • Now
Bitcoin holds below $68,000 as market awaits signals from ETFs and Fed
  • Anton Kharitonov
  • Now
WTI updates local lows as returning supply and fading geopolitical risk premium weigh on prices
  • Mykhailo Ihnatenko
  • Now
Unilever balances AI ambitions and weak sales
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR